Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma | Cancer Research
AS is a key regulator of most hallmarks of cancer (30–32), which has recently been investigated as a novel source of neoantigens (33). In this study, immunohistochemical analysis of ICC TMA identified that AS for CD44 occurs predominantly in ICC tumor tissue, but not in normal human tissue, and the potential role of CD44v as …